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Background. People with HIV (PWH) may experience accentuating aging in relation to immuno-activation. Little is known 
regarding thymus (THY) involution in this process. We sought to investigate the relationship between THY imaging detection/size 
and clinically relevant aging outcomes such as metabolic syndrome (MetS), multimorbidity (MM), and frailty in PWH.
Methods. This was a cross-sectional observational study including 665 HIV patients (81% males; median age, 53  years) at-
tending Modena HIV Metabolic Clinic from 2014 to 2017. They underwent thoracic computed tomography scan as part of the med-
ical assessment for cardiovascular disease, in which THY detection and size were reported using a semiquantitative score. Outcome 
measures were MetS, MM, and frailty.
Results. THY was detected in 27.0% of subjects; 71.1% showed THY size of grade 1–2, and 28.9% exhibited grade ≥3. Covariates 
that inversely correlated with THY detection were age, male gender, body mass index (BMI), and HIV duration. Covariates that in-
versely correlated with MetS were age, HIV duration, BMI, and THY grade 1–2. Covariates that inversely correlated with MM were 
age, HIV duration, and CD4 nadir. Covariates that inversely correlated with frailty were age, HIV duration, CD4 nadir, BMI, and 
THY detection.
Conclusions. THY is inversely associated with MetS and frailty in PWH.
Keywords. aging; frailty; HIV; metabolic syndrome; thymus.
Thymus (THY) is a primary lymphoid organ, visible in the 
upper mediastinum beneath the sternum. It is the primary 
site of T-cell selection, development, and maturation. THY 
size and function decline across time: They are more conspic-
uous at the onset of puberty [1]; afterwards, they decrease by 
~3% per year until middle age, and subsequently by 1% per 
year [2]. Loss of THY function has been described as an inde-
pendent predictor of all-cause mortality in uninfected elderly 
humans [3].
Although THY involution affects all individuals, this physio-
logical process may vary from one subject to another. Moreover, 
it can be greatly influenced by several pathological conditions 
that affect the immune system, such as HIV infection [4, 5].
THY size has been shown to predict CD4 recovery and higher 
CD4/CD8 ratio after antiretroviral therapy (ART) initiation [6] 
and to be related to the dramatic increase in CD4 T-cell count 
found in late presenters [5]. Furthermore, age-related THY de-
cline may have an impact on the inability of either children or 
adults to restore immune function following HIV infection [7].
Much less is known regarding the role of THY in immune 
activation, which characterizes accentuating aging processes 
in people with HIV (PWH), as defined by the increased 
prevalence of age-related comorbidity and frailty observed 
in comparison with the general population [8, 9]. At a clin-
ical level, this immuno-metabolic phenomenon is often de-
scribed as “inflammaging” [10, 11], and it is pathogenically 
linked with metabolic syndrome (MetS) [12], noninfectious 
comorbidities (NICMs) [13, 14], functional decline [15], 
and geriatric syndromes including frailty [16]. Geriatric 
syndromes are better suited than single comorbidities to 
predicting age-related outcomes in PWH [17]. Frailty, in par-
ticular, measures the biological age of individuals regardless 
of their chronological age. It is conceptualized as a reduction 
of physiologic reserves related to a greater risk of hospitaliza-
tion, disability, and mortality [18, 19].
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We hypothesized that THY may play an important role in 
clinically relevant aging outcomes in PWH, and thus we sought 
to investigate the association between thymus imaging detec-




This was an observational study including HIV patients at-
tending Modena HIV Metabolic Clinic (MHMC) from 2014 to 
2017. In this tertiary care teaching hospital in Northern Italy, 
all individuals are screened by a multidisciplinary team for 
immuno-metabolic disorders, HIV-associated NICMs, geriatric 
syndromes, and frailty. In this center of excellence, the national 
health service offers patients, free of charge, thoracic and abdom-
inal computed tomography (CT) to detect coronary artery cal-
cium (CAC), lung parenchyma abnormalities, visceral adipose 
tissue, and liver steatosis. CAC assessment is routinely used as 
a risk modifier for cardiovascular risk stratification. THY detec-
tion is reported in the description of radiological findings.
In this cross-sectional study, we included 665 consecutive 
HIV patients undergoing ART for at least 2 years with a stable 
undetectable viral load (<40 copies/mL). No exclusion criteria 
were defined. Patients were evaluated for immuno-metabolic 
abnormalities, NICM, and frailty on the same day when tho-
racic CT scan was performed.
THY detection and size were retrospectively graded using a 
semiquantitative score describing the size and appearance of 
THY solid tissue in the anterior mediastinum (0 = not detected; 
1 = minimal soft tissue barely recognizable, 1%–25%; 2 = min-
imal soft tissue more obvious, 26%–50%; 3  =  moderate soft 
tissue, 51%–75%; 4  =  moderate, almost mass-like, soft tissue, 
75%–100%; 5 = mass-like soft tissue), as previously described 
[20–22].
In this semiquantitative grading system, THY is detected and 
evaluated by tissue density and size (picture examples from this 
cohort are shown in Supplementary Figure 1, where borders are 
manually drawn to visually show THY size).
This study was approved by the University of Modena and 
Reggio Emilia ethics committee according to the Declaration 
of Helsinki. All patients provided written consent before 
participating in the study.
Outcome Measures
Metabolic disorder was defined using MetS ATPIII classifica-
tion [23], including 3 or more of the following 5 criteria: waist 
circumference >102 cm (men) or >88 cm (women), blood pres-
sure >130/85 mmHg, fasting triglyceride (TG) level >150 mg/
dL, fasting high-density lipoprotein (HDL) cholesterol level 
<40 mg/dL (men) or <50 mg/dL (women), and fasting blood 
glucose >100  mg/dL. Homeostasis model assessment of in-
sulin resistance (HOMA-IR) was calculated using the following 
formula: HOMA-IR  =  [fasting glucose (mg/dL) × fasting in-
sulin (mU/mL)]/405 [24].
NICMs were defined according to European AIDS 
Clinical Society (EACS) guidelines [25]. Cardiovascular 
disease (CVD) included myocardial infarction, coronary 
artery disease, peripheral vascular disease, stroke, and an-
gina pectoris, as well as coronary artery bypass grafting and 
angioplasty, based on diagnoses recorded in patient files. 
Hypertension (HTN) was defined as 2 consecutive meas-
urements of blood pressure >140/90  mmHg; dyslipidemia 
(DLP) as elevated total or low-density lipoprotein choles-
terol or low high-density lipoprotein cholesterol above lab-
oratory limits; type 2 diabetes mellitus (T2DM) as fasting 
serum glucose levels >126 mg/dL or HbA1C >6.5%; chronic 
kidney disease (CKD) as an estimated glomerular filtration 
rate (eGFR) of <60  mL/min/1.73 m2, calculated using the 
Chronic Kidney Disease Epidemiology Collaboration (CKD-
Epi) equation; osteoporosis in postmenopausal women and 
men aged ≥50  years as a bone mass index (BMD) T-score 
≤–2.5 and in premenopausal women and men aged <50 years 
as a BMD Z-score ≤–2 and fragility fracture; chronic ob-
structive pulmonary disease (COPD) as postbronchodilator 
FEV1/FVC  <0.70 with spirometry. Liver cirrhosis was as-
sessed in every patient and was defined through noninva-
sive assessment with either serum biomarkers (FIB-4) or 
transient elastography [26]. Lipodystrophy was described 
as lipoatrophy, lipohypertrophy, or mixed form a fat redis-
tribution [27]. Laboratory values for the diagnosis of CKD 
and DLP were confirmed in 2 consecutive measurements. 
Diagnoses of DLP, HTN, and T2DM were also identified 
based on current use of lipid-lowering, antihypertensive, or 
antidiabetic drugs. The following comorbidities were not in-
cluded if they had not been collected routinely and in a stand-
ardized fashion: cancer, sexual dysfunction, neurocognitive 
impairment, or depression.
Multimorbidity (MM) was defined as presence ≥3 
comorbidities in the same individual. Frailty was measured 
with both the frailty phenotype (FP) and a 37-item frailty 
index (FI) previously validated at MHMC and constructed 
from health variables collected at the same study visit [28]. 
Each variable included in the FI was coded with a value of 1 
when a deficit was present and 0 when it was absent. Missing 
values were removed from both the numerator and the de-
nominator of the FI [29]. In the logistic analyses, FI >0.4 was 
used to identify most frail individuals. The FP is based on a 
predefined set of 5 criteria exploring the presence/absence of 
signs or symptoms (involuntary weight loss, exhaustion, slow 
gait speed, poor handgrip strength, and sedentary behavior). 
The number of criteria (a 6-level ordinal variable ranging from 
0 to 5) is categorized as a 3-level variable depicting robustness 
(meets none of the criteria), prefrailty (meets 1 or 2 criteria), 
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Statistical Analyses
Results were expressed as mean and standard deviation or me-
dian and interquartile range (IQR) for continuous variables 
based on the normality of distribution, and as frequencies and 
percentages for categorical variables. The Student t test was 
applied to identify statistical difference for continuous vari-
ables with normal distribution, whereas the Mann-Whitney 
test was used for those without normal distribution. The χ 2 
test was performed to assess the frequency of the categorical 
variables.
A backwards stepwise logistic regression analysis was con-
ducted to identify independent predictors for THY detection by 
using as covariates age, gender, and statistically significant pre-
dictors identified in univariate analyses, including cumulative 
exposure to ART. To avoid collinearity between age and dura-
tion of HIV, the latter was calculated from univariate linear re-
gression between age and duration of HIV infection, depicting 
the effect of HIV duration after correction for age (in Figure 1, 
called “residual of HIV duration”).
A logistic regression analysis was conducted to identify inde-
pendent predictors for MetS, MM, and FI by using as covariates 
age, gender, THY detection (using THY  =  0 as reference), 
and statistically significant predictors identified in univariate 
analyses.
A P value cutoff <.05 was chosen for all statistical analyses, 
performed using R software, version 3.4.1.
RESULTS
A total of 665 HIV-infected patients (81% males) were included 
(median age, 53 years; median CD4, 730/μL).
Thymus Detection and Associated Factors
THY was detected in 180 (27.0%) of 665 subjects. In these indi-
viduals, the mean age was 49.1 ± 6.9 years, and the current CD4 
count was 764.7 ± 298.1 c/µL. In patients in whom THY was 
not detected, the mean age was 45.6 ± 7.9 years, and the current 
CD4 count was 718.2 ± 342.4 c/µL. Among subjects with a de-
tectable THY, 128 (71.1%) showed a size of grade 1–2, and 52 
(28.9%) exhibited grade 3 or higher.
THY was detected in 45.0% of HIV patients aged <50 years 
(26.0% THY 1–2 and 19.0% THY ≥3), 21.4% of HIV patients aged 
50–65 years (18.0% THY 1–2 and 3.4% THY ≥3), and 3.8% of HIV 
patients >65 years (all THY 1–2) (Supplementary Figure 2A). 
THY was found in 43.2%, 30.1%, and 22.1% of subjects with 
<10, 10–20, and >20  years of HIV duration, respectively 
(Supplementary Figure 2B).
Univariate analysis was built to describe demographic, an-
thropometric, and HIV variables and study outcomes according 
to THY detection and size. High statistically significant differ-
ences were found between THY detection and size and the fol-
lowing demographic and anthropometric measures: age, male 
sex, BMI, waist circumference, lipodystrophy, and cumulative 
exposure to PI and NRTI (P < .001) but not NNRTI and INSTI 
(Table 1).
Shorter HIV duration expressed in months was associ-
ated with a higher prevalence of THY detection in our co-
hort (P <  .001), whereas other traditional HIV variables used 
in routine clinical assessment in PWH were not statistically 
significant.
Lower levels of immuno-metabolic measures such as total 
cholesterol, triglycerides, HOMA-IR, HbA1C, CKD-epi, CRP, 
and CAC were related to THY detection and size, all of which 
reached statistical significance.
With regard to comorbidities, DLP, HTN, and T2DM were 
significantly and inversely associated with THY detection and 
size (P < .001).
In a multivariate logistic model, negative predictors for 
THY detection were older age (odds ratio [OR],  0.92; 95% 
confidence interval [CI], 0.89–0.94), male gender (OR, 0.43; 
95% CI, 0.27–0.70), and higher BMI (OR,  0.90; 95% CI, 
0.84–0.96), as depicted in Figure 1. Cumulative exposure to 
NRTI and PI were not independently associated with study 
outcome.
Thymus and Clinical Outcomes
THY detection and size were evaluated in relation to the fol-
lowing clinical outcomes: MetS, MM, and FI. An inverse associ-
ation was found between THY and MetS (P < .01) (Figure 2A), 
MM (P  <  .01) (Figure 2B), and FI (P  <  .01) (Figure 2C) 
prevalence.
Univariate analysis demonstrated that age (OR,  1.06; 95% 
CI, 1.03–1.09), BMI (OR, 1.20; 95% CI, 1.14–1.28), THY 1–2 
(OR,  0.23; 95% CI, 0.09–0.47), THY  ≥3 (OR,  0.34; 95% CI, 
0.10–0.87), and HIV duration (OR,  1.03; 95% CI, 1.01–1.06) 
were significantly related to MetS, whereas traditional HIV fac-
tors did not correlate with it. MM and FI were associated with 
higher BMI (MM OR,  1.09; 95% CI, 1.04–1.15; FI OR,  1.10; 
95% CI, 1.05–1.15), older age (MM OR,  1.17; 95% CI, 1.14–
1.21; FI OR, 1.06; 95% CI, 1.04–1.09), nadir CD4 100–350 c/
µL (vs 100 c/µL; MM OR, 0.41; 95% CI, 0.26–0.63; FI OR, 0.61; 
95% CI, 0.41–0.89), nadir CD4 350–500 c/µL (vs 100 c/µL; MM 
OR, 0.38; 95% CI, 0.21–0.70; FI OR, 0.42; 95% CI, 0.24–0.75), 
current CD4 count ≥500 c/µL (vs 350 c/µL; MM OR, 0.55; 95% 
CI, 0.27–1.06; FI OR, 0.47; 95% CI, 0.26–0.83), and longer HIV 
duration (MM OR, 1.10; 95% CI, 1.07–1.12; FI OR, 1.07; 95% 
CI, 1.05–1.10) (Supplementary Table 1).
To better explore these associations, multivariate logistic models 
were built. Independent predictors for MetS were older age (OR, 1.04; 
95% CI, 1.01–1.07), longer HIV duration (OR, 1.04; 95% CI, 1.01–
1.08), higher BMI (OR,  1.19; 95% CI, 1.12–1.27), and THY 1–2 
(OR, 0.33; 95% CI, 0.13–0.70), as shown in Figure 3A. Independent 
predictors for MM were older age (OR,  1.16; 95% CI, 1.12–1.20), 
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100–350 vs <100 c/µL (OR, 0.39; 95% CI, 0.23–0.66) (Figure 3B). 
Independent predictors for FI were older age (OR,  1.05; 95% CI, 
1.02–1.07), longer HIV duration (OR, 1.06; 95% CI, 1.03–1.09), nadir 
CD4 100–350 vs <100 c/µL (OR, 0.58; 95% CI, 0.38–0.90), higher 
BMI (OR, 1.10; 95% CI, 1.04–1.16), THY 1–2 (OR, 0.59; 95% CI, 
0.35–0.97), and THY ≥3 (OR, 0.32; 95% CI, 0.11–0.82) (Figure 3C).
DISCUSSION
This is the first study to explore the relationship between detection 
and size of the thymus and metabolic syndrome, multimorbidity, 
and frailty in PWH. In fact, to the best of our knowledge, even 
general population studies have never explored THY as a predictor 
of immuno-metabolic and geriatric outcomes in large cohorts [31].
Table 1. Demographic, Anthropometric, Relevant HIV and Immuno-Metabolic Markers, Comorbidities, and Study Outcomes According to THY Detection 
and Size
Total THY = 0 THY 1–2 THY ≥ 3 P
THY detection 665 485 (72.93) 128 (19.25) 52 (7.82)  
Demographics and anthropometry      
Age, mean (SD) [No.] 53.11 (7.98) [665] 54.59 (7.86) [485] 50.92 (6.36) [128] 44.69 (6.13) [52] <.001
Male, No. (%) 539 (81.05) 412 (84.95) 92 (71.88) 35 (67.31) <.001
BMI, mean (SD), kg/m2 [No.] 24.15 (3.78) [615] 24.57 (3.97) [449] 23.22 (3.05) [120] 22.45 (2.51) [46] <.001
Waist circumference, mean (SD), cm 
[No.]
89.67 (10.89) [628] 91.27 (10.94) [450] 86.65 (9.86) [122] 82.03 (7.78) [46] <.001
Lipoatrophy, No. (%) [No.] 102 (29.91) [665] 74 (29.96) [485] 22 (32.84) [128] 6 (22.22) [52] <.001
Lipohypertrophy, No. (%) [No.] 36 (10.56) [665] 32 (12.96) [485] 2 (2.99) [128] 2 (7.41) [52] <.001
Mixed form, No. (%) [No.] 107 (31.38) [665] 92 (37.25) [485] 15 (22.39) [128] 0 (0) [52] <.001
HIV-related variables      
HIV duration, median (IQR), mo [No.] 262 (183.25–323) [658] 267 (197–327.5) [479] 259 (180–319.5) [127] 171 (87.25–251.75) [52] <.001
HIV risk: IVDU, No. (%) [No.] 174 (26.17) [665] 141 (29.07) [485] 28 (21.88) [128] 5 (9.62) [52] .022
HIV risk: MSM, No. (%) [No.] 234 (35.19) [665] 167 (34.43) [485] 42 (32.81) [128] 25 (48.08) [52] .022
HBV co-infection, No. (%) [No.] 13 (2.13) [611] 12 (2.67) [450] 1 (0.87) [115] 0 (0) [46] .286
HCV co-infection, No. (%) [No.] 159 (26.46) [601] 116 (26.13) [444] 36 (31.03) [116] 7 (17.07) [41] .209
Nadir CD4, median (IQR), c/µL [No.] 200.5 (94.25–300) [642] 200 (88–300) [473] 216.5 (99–301) [120] 240 (110–318) [49] .356
Current CD4/CD8, mean (SD) [No.] 0.96 (0.62) [539] 0.96 (0.68) [399] 0.95 (0.48) [99] 0.97 (0.36) [41] .399
Current CD4, mean (SD), c/µL [No.] 730.61 (330.52) [652] 718.2 (342.38) [476] 758.19 (287.33) [126] 779.26 (313.92) [50] .102
Current CD38, mean (SD), c/µL [No.] 59.5 (86.22) [321] 59.83 (89.76) [235] 47.74 (61.99) [66] 94.5 (105.05) [20] .120
Cumulative exposure to NRTI, median  
(IQR), mo [No.]
158.5 (87.75–210.25) [628] 167.5 (98–213) [458] 142 (79.25–201.25) [122] 100.5 (57.75–169.25) [48] <.001
Cumulative exposure to NNRTI, 
median (IQR), mo [No.]
61 (25–115) [485] 61.5 (24.25–114.75) [358] 64 (26–132) [93] 50.5 (25.5–92.5) [34] .551
Cumulative exposure to PI, 
median (IQR), mo [No.]
97.5 (48–154.75) [542] 105 (51.5–162.5) [407] 93 (46–137) [97] 55.5 (30–97.5) [38] <.001
Cumulative exposure to INSTI, median 
(IQR), mo [No.]
39 (17–68.5) [251] 37 (16–69.25) [200] 48.5 (34–64.75) [38] 35 (17–68) [13] .538
Immuno-metabolic variables      
Total cholesterol, mean (SD),  
mg/dL [No.]
184.78 (40.2) [630] 183.57 (40.25) [463] 188.96 (38.47) [120] 186.06 (43.96) [47] .415
Tryglycerides, mean (SD), mg/dL [No.] 159.42 (113.15) [628] 169.98 (123.63) [461] 133.1 (71.42) [120] 123 (64.65) [47] <.001
HOMA-IR, mean (SD) [No.] 2.96 (5.31) [498] 3.39 (6.09) [368] 1.87 (1.23) [92] 1.38 (0.69) [38] <.001
HbA1C, mean (SD), mmol/mol [No.] 27.49 (16.2) [487] 28.62 (16.68) [356] 26.4 (13.91) [90] 20.14 (15.01) [41] .005
CKD-Epi, mean (SD), mil/min [No.] 88.6 (18.17) [607] 86.42 (18.69) [445] 93.05 (15.29) [117] 98.61 (14.24) [45] <.001
CRP, mean (SD), mg/L [No.] 0.3 (0.37) [617] 0.31 (0.38) [450] 0.29 (0.38) [120] 0.22 (0.19) [47] .013
CAC, median (IQR) [No.] 2 (0–78.25) [640] 11 (0–112.75) [462] 0 (0–23.5) [127] 0 (0-0) [51] <.001
Comorbidities      
DLP, No. (%) [No.] 574 (86.32) [665] 431 (88.87) [485] 106 (82.81) [128] 37 (71.15) [52] .001
HTN, No. (%) [No.] 337 (50.68) [665] 276 (56.91) [485] 51 (39.84) [128] 10 (19.23) [52] <.001
CVD, No. (%) [No.] 43 (6.47) [665] 39 (8.04) [485] 3 (2.34) [128] 1 (1.92) [52] .025
T2DM, No. (%) [No.] 120 (18.05) [665] 110 (22.68) [485] 8 (6.25) [128] 2 (3.85) [52] <.001
CKD, No. (%) [No.] 101 (15.19) [665] 83 (17.11) [485] 17 (13.28) [128] 1 (1.92) [52] .012
COPD, No. (%) [No.] 42 (6.32) [665] 31 (6.39) [485] 10 (7.81) [128] 1 (1.92) [52] .335
Osteoporosis, No. (%) [No.] 173 (26.02) [665] 131 (27.01) [485] 31 (24.22) [128] 11 (21.15) [52] .576
Liver cirrhosis, No. (%) [No.] 85 (12.78) [665] 68 (14.02) [485] 14 (10.94) [128] 3 (5.77) [52] .187
Abbreviations: BMI, body mass index; CAC, coronary artery calcium; CKD, chronic kidney disease; CKD-Epi, Chronic Kidney Disease Epidemiology Collaboration; COPD, chronic obstructive pulmo-
nary disease; CRP, C-reactive protein; CVD, cardiovascular disease; DLP, dyslipidemia; HBV, hepatitis B virus; HCV, hepatitis C virus; HOMA-IR, homeostatic model assessment-insulin resistance; 
HTN, hypertension; INSTIs, integrase strand transfer inhibitors; IQR, interquartile range; IVDU, intravenous drug user; MetS, metabolic syndrome; MM, multimorbidity; MSM, men who have sex 
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THY was detected in 27.0% of PWH in our cohort, showing a 
decreasing prevalence with age, along with a presence of 19.4% in 
PWH over 50 years of age (although in only in 3.8% of patients 
>65 years). The lack of a control group in our study prevents us 
from comparing these data with the general population. In a pre-
vious study comparing 99 HIV-positive patients with 32 HIV-
negative controls with median age <40 years, THY tissue persisted 
in HIV-positive patients only [32], suggesting that this organ invo-
lution might be specific to PWH. Interestingly, the authors from 
this study suggested a possible survival bias to explain this phe-
nomenon in HIV patients. The same bias cannot be ruled out in 
our cohort either. Moreover, it must be taken into account that a 
functional thymus has been described in healthy centenarians [33].
THY involution is a time-dependent variable that is defini-
tively associated with age but, independently from that, is also 
associated with HIV duration. This finding from our cohort is 
consistent with previous studies [34]. We argue that this HIV 
duration effect may be related to the chronic immuno-activation 
process specific to PWH, regardless of exposure to effective 
ART [34, 35] and not captured by HIV variables routinely used 
to monitor HIV disease. It is therefore not surprising that CD4 
count and viral load were not associated with THY.
THY was inversely associated with CRP and a constella-
tion of metabolic disorders, reinforcing the conceptualization 
of immune-metabolic disorder. We believe that these findings 
fit the “metaflammation” construct [36]. Metaflammation has 
been described as an inflammatory cell action present in the 
liver, brain, pancreas, adipose tissue, lymph nodes, and pre-
sumably in THY, as the result of inflammatory cell interactions 
within the stromal components in these organs. These tissues 
and mediators cause systemic inflammatory responses and dis-
rupt metabolic homeostasis. As a result, immuno-metabolic dis-
eases often emerge as clusters and promote aging, disability, and 
premature death. We therefore suggest that “metaflammation” 
justifies the inverse statistical association between THY de-
tection/size and DLP, HTN, CKD, CVD, and T2DM found in 
our study.
CD4 current 500+















Figure 1. Predictors of thymus detection at multivariate logistic model. 
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Figure 2. Association between thymus detection and size, and metabolic syn-
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This study chose MetS, MM, and frailty as relevant geriatric 
outcomes. THY was an independent predictor for MetS after 
correction for BMI, age, and HIV duration. The lack of associa-
tion between these outcomes and THY size (THY ≥ 3) may just 
reflect the small sample size of this group.
As the NICM-and-MM construct does not necessarily reflect 
the clinical complexity of aging, we sought to portray biological age 
with regards to frailty [17]. The association between THY and age 
is expected; on the contrary, the association with a measure of bio-
logical age, which depicts health outcomes better than chronolog-
ical age, has never been described even in the general population. 
We have previously compared FP and FI in our cohort. Although 
these 2 tools display similar characteristics in our cohort, FI had a 
stronger association with age, comorbidities, geriatric syndromes, 
and disability [29]. Therefore, we were not surprised that FI, but 
not FP, was associated with THY.
The strong correlation between FI and smaller THY size, 
after correction for age, BMI, CD4 nadir, and HIV duration, 
confirms that this geriatric syndrome, possibly measured 
with an index, is connected with immune system dysfunc-
tion. Smaller THY size reflects reduced THY function [4]. We 
therefore believe that THY involution is a component of the 
complex clinical spectrum of aging in PWH. This is meant 
to be a hypothesis-generating study regarding a novel mech-
anism that regulates aging trajectories in PWH. Prospective 
studies comparing children who acquired HIV at birth 
with noninfected children to confirm this observation are 
needed. THY is an organ in which T cells differentiate and 
mature, giving origin to all peripheral T-cell populations, 
which have different functions and activities. Indeed, cells 
that derive from THY not only include those that regulate 
and dampen the immune response (ie, regulatory T cells), 
THY 3+
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Figure 3. Multivariate analysis for the association between thymus detection and size, and metabolic syndrome (A), multimorbidity (B), and frailty index (C). Abbreviations: 
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but also those capable of triggering inflammatory pathways 
(such as Th17). Thus, it is unclear whether THY may actu-
ally have a protective role in the “inflammaging” process, or 
if the same pathogenic pathways leading to chronic inflam-
mation, metabolic changes, and ultimately disability lead 
to faster THY involution. Future research should focus on 
the pathogenic mechanisms behind THY involution, on the 
ways to preserve its function, and on the frequency of dif-
ferent categories of peripheral T cells.
This study has a number of limitations. Some of these are 
intrinsic to the cross-sectional nature of the study, which 
cannot reveal any causative association between variables. 
Moreover, we cannot prove that smaller THY size is associated 
with reduced THY function. The absence of a control group 
does not allow us to show whether HIV variables associated 
both with THY and outcome measures represent a true spec-
ificity of these findings in PWH, compared with the general 
population.
The retrospective nature of our study did not allow us to 
measure THY function. The correlation of thymic mass with 
thymic function remains under investigation. Evidence exists 
for extrathymic thymopoieseis, non-thymic-dependent T-cell 
maturation mechanisms, IL-7-related effects, and others factors 
affecting T-cell function. It is unknown how these factors in-
teract in treated PWH and whether there are age-related differ-
ences in these mechanisms.
On the other hand, as previously mentioned, this is one of 
the largest cohorts ever to describe THY detection and size in 
an HIV setting.
In conclusion, our study defines THY as an indicator of bi-
ological aging in PWH predicting metabolic syndrome and 
frailty. Future studies should focus on assessing the impact of 
THY detection in relation to function and to other relevant 
health variables such as hospitalization, disability, and quality 
of life.
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